We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead (GILD) Misses Q1 Earnings and Revenue Estimates, Stock Drops
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) just released its first quarter fiscal 2017 financial results, posting earnings of $2.23 per share and revenues of $6.5 billion. GILD is a #2 (Buy) on the Zacks Rank, and is down 1.66% to $6.45 per share in trading shortly after its earnings report was released.
Gilead:
Missed earnings estimates. The company reported earnings of $2.23 per share, falling short of the Zacks Consensus Estimate of $2.25 per share. This number excludes 18 cents from non-recurring items.
Missed revenue estimates. The company saw revenue figures of $6.5 billion, missing the Zacks Consensus Estimate of $6.66 billion and declining 16.4% year-over-year.
Gilead reported total product sales of $6.4 billion for Q1, compared to $7.7 billion in the same period in 2016. Antiviral product sales, which include sales of its HIV, chronic hepatitis B (HBV) and chronic hepatitis C (HCV) products, were $5.8 billion for the first quarter.
Regionally, Product sales in Q1 were $4.5 billion in the United States, $1.3 billion in Europe, and $661 million in other locations.
The company reiterated its full-year 2017 guidance. Gilead expects net product sales in the range of $22.5 billion and $24.5 billion, and product gross margin between 86% and 88%. Diluted EPS is forecasted in the range of 84 cents to 91 cents per share.
Here’s a graph that looks at Gilead’s price, consensus, and EPS surprise:
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead (GILD) Misses Q1 Earnings and Revenue Estimates, Stock Drops
Gilead Sciences (GILD - Free Report) just released its first quarter fiscal 2017 financial results, posting earnings of $2.23 per share and revenues of $6.5 billion. GILD is a #2 (Buy) on the Zacks Rank, and is down 1.66% to $6.45 per share in trading shortly after its earnings report was released.
Gilead:
Missed earnings estimates. The company reported earnings of $2.23 per share, falling short of the Zacks Consensus Estimate of $2.25 per share. This number excludes 18 cents from non-recurring items.
Missed revenue estimates. The company saw revenue figures of $6.5 billion, missing the Zacks Consensus Estimate of $6.66 billion and declining 16.4% year-over-year.
Gilead reported total product sales of $6.4 billion for Q1, compared to $7.7 billion in the same period in 2016. Antiviral product sales, which include sales of its HIV, chronic hepatitis B (HBV) and chronic hepatitis C (HCV) products, were $5.8 billion for the first quarter.
Regionally, Product sales in Q1 were $4.5 billion in the United States, $1.3 billion in Europe, and $661 million in other locations.
The company reiterated its full-year 2017 guidance. Gilead expects net product sales in the range of $22.5 billion and $24.5 billion, and product gross margin between 86% and 88%. Diluted EPS is forecasted in the range of 84 cents to 91 cents per share.
Here’s a graph that looks at Gilead’s price, consensus, and EPS surprise:
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. Price, Consensus and EPS Surprise | Gilead Sciences, Inc. Quote
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>